Aeterna Zentaris Announces Novo Nordisk to acquire rights to Macrilen™ in United States and Canada
November 01 2018 - 8:00AM
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS)
announces that it was advised yesterday that Strongbridge BioPharma
Plc has signed an agreement with Novo Nordisk A/S pursuant to which
Novo Nordisk will acquire from Strongbridge Biopharma Plc its
rights to Macrilen™ in the United States and Canada.
Aeterna Zentaris has licensed the rights to Macrilen™ in the
United States and Canada to Strongbridge Biopharma.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty
biopharmaceutical company focused on developing and
commercializing, principally through out-licensing arrangements,
Macrilen™ (macimorelin), an oral ghrelin receptor agonist, to be
administered in the diagnosis of patients with adult growth hormone
deficiency. Aeterna Zentaris has entered into a license and
assignment agreement with a wholly-owned subsidiary of Strongbridge
Biopharma plc to carry out development, manufacturing, registration
and commercialization of Macrilen™ (macimorelin) in the United
States and Canada. For more information, visit
www.zentaris.com.
Contact:
Leslie AuldChief Financial OfficerAeterna Zentaris
Inc.IR@aezsinc.com843-900-3201
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Sep 2023 to Sep 2024